{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T10:49:12Z","timestamp":1794134952075,"version":"4.8.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T00:00:00Z","timestamp":1564963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T00:00:00Z","timestamp":1564963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s10637-019-00832-1","type":"journal-article","created":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T10:02:40Z","timestamp":1564999360000},"page":"844-854","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma"],"prefix":"10.1007","volume":"38","author":[{"given":"Shahneen","family":"Sandhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catriona M.","family":"McNeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"LoRusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Kabbarah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunze","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Sanabria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Michael","family":"Flanagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru-Fang","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Brunstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Nazzal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney","family":"Hicks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Lemahieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Infante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,5]]},"reference":[{"key":"832_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RLMK Siegel","year":"2018","unstructured":"Siegel RLMK, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68:7\u201330","journal-title":"CA Cancer J Clin"},{"key":"832_CR2","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1158\/2159-8290.CD-13-0617","volume":"4","author":"EM Van Allen","year":"2014","unstructured":"Van Allen EM, Wagle N, Sucker A, Treacy DJ, Johannessen CM, Goetz EM, Place CS, Taylor-Weiner A, Whittaker S, Kryukov GV, Hodis E, Rosenberg M, McKenna A, Cibulskis K, Farlow D, Zimmer L, Hillen U, Gutzmer R, Goldinger SM, Ugurel S, Gogas HJ, Egberts F, Berking C, Trefzer U, Loquai C, Weide B, Hassel JC, Gabriel SB, Carter SL, Getz G, Garraway LA, Schadendorf D, Dermatologic Cooperative Oncology Group of Germany (DeCOG) (2014) The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov 4:94\u2013109","journal-title":"Cancer Discov"},{"key":"832_CR3","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A (2017) Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168:707\u2013723","journal-title":"Cell"},{"key":"832_CR4","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.critrevonc.2018.03.005","volume":"125","author":"M Wahid","year":"2018","unstructured":"Wahid M, Jawed A, Mandal RK, Dar SA, Akhter N, Somvanshi P, Khan F, Lohani M, Areeshi MY, Haque S (2018) Recent developments and obstacles in the treatment of melanoma with BRAF and MEK inhibitors. Crit Rev Oncol Hematol 125:84\u201388","journal-title":"Crit Rev Oncol Hematol"},{"key":"832_CR5","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1158\/0008-5472.CAN-03-2344","volume":"64","author":"A Bagnato","year":"2004","unstructured":"Bagnato A, Rosan\u00f2 L, Spinella F, Di Castro V, Tecce R, Natali PG (2004) Endothelin B receptor blockade inhibits dynamics of cell interactions and communications in melanoma cell progression. Cancer Res 64:1436\u20131443","journal-title":"Cancer Res"},{"key":"832_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrd3320","volume":"10","author":"R Lappano","year":"2011","unstructured":"Lappano R, Maggiolini M (2011) G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov 10:47\u201360","journal-title":"Nat Rev Drug Discov"},{"key":"832_CR7","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/j.1755-148X.2010.00678.x","volume":"23","author":"A Saldana-Caboverde","year":"2010","unstructured":"Saldana-Caboverde A, Kos L (2010) Roles of endothelin signaling in melanocyte development and melanoma. Pigment Cell Melanoma Res 23:160\u2013170","journal-title":"Pigment Cell Melanoma Res"},{"key":"832_CR8","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1158\/1078-0432.CCR-10-2340","volume":"17","author":"J Asundi","year":"2011","unstructured":"Asundi J, Reed C, Arca J, McCutcheon K, Ferrando R, Clark S, Luis E, Tien J, Firestein R, Polakis P (2011) An antibody-drug conjugate targeting the endothelin B receptor for the treatment of melanoma. Clin Cancer Res 17:965\u2013975","journal-title":"Clin Cancer Res"},{"key":"832_CR9","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s004280000362","volume":"438","author":"A Demunter","year":"2001","unstructured":"Demunter A, De Wolf-Peeters C, Degreef H, Stas M, van den Oord JJ (2001) Expression of the endothelin-B receptor in pigment cell lesions of the skin. Evidence for its role as tumor progression marker in malignant melanoma. Virchows Arch 438:485\u2013491","journal-title":"Virchows Arch"},{"key":"832_CR10","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nrc990","volume":"3","author":"J Nelson","year":"2003","unstructured":"Nelson J, Bagnato A, Battistini B, Nisen P (2003) The endothelin axis: emerging role in cancer. Nat Rev Cancer 3:110\u2013106","journal-title":"Nat Rev Cancer"},{"key":"832_CR11","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/35020115","volume":"406","author":"M Bittner","year":"2000","unstructured":"Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix M, Radmacher M, Simon R, Yakhini Z, Ben-Dor A, Sampas N, Dougherty E, Wang E, Marincola F, Gooden C, Lueders J, Glatfelter A, Pollock P, Carpten J, Gillanders E, Leja D, Dietrich K, Beaudry C, Berens M, Alberts D, Sondak V (2000) Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406:536\u2013540","journal-title":"Nature"},{"key":"832_CR12","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1038\/sj.bjc.6600620","volume":"87","author":"SL Smith","year":"2002","unstructured":"Smith SL, Damato BE, Scholes AG, Nunn J, Field JK, Heighway J (2002) Decreased endothelin receptor B expression in large primary uveal melanomas is associate with early clinical metastasis and short survival. Br J Cancer 87:1308\u20131313","journal-title":"Br J Cancer"},{"key":"832_CR13","doi-asserted-by":"crossref","first-page":"17141","DOI":"10.1016\/S0021-9258(17)44880-0","volume":"265","author":"R Bai","year":"1990","unstructured":"Bai R, Pettit GR, Hamel E (1990) Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. J Biol Chem 265:17141\u201317149","journal-title":"J Biol Chem"},{"key":"832_CR14","doi-asserted-by":"crossref","unstructured":"Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, DeBlanc RL, Gearing RP, Bovee TD, Siegall CB, Francisco JA, Wahl AF, Meyer DL, Senter PD (2003) Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 21:778\u201384, 784","DOI":"10.1038\/nbt832"},{"key":"832_CR15","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","volume":"102","author":"JA Francisco","year":"2003","unstructured":"Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, Rejniak SX, Gordon KA, DeBlanc R, Toki BE, Law CL, Doronina SO, Siegall CB, Senter PD, Wahl AF (2003) cAC10-vcMMAE, an anti-CD30\u2212monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102:1458\u20131465","journal-title":"Blood"},{"key":"832_CR16","doi-asserted-by":"crossref","unstructured":"Okeley NM, Miyamoto JB, Zhang X, Sanderson RJ, Benjamin DR, Sievers EL, Senter PD, Alley SC (2010) Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res 16:888\u201397, 897","DOI":"10.1158\/1078-0432.CCR-09-2069"},{"key":"832_CR17","doi-asserted-by":"publisher","first-page":"8664","DOI":"10.1074\/jbc.275.12.8664","volume":"275","author":"Y Abe","year":"2000","unstructured":"Abe Y, Nakayama K, Yamanaka A, Sakurai T, Goto K (2000) Subtype-specific trafficking of endothelin receptors. J Biol Chem 275:8664\u20138671","journal-title":"J Biol Chem"},{"key":"832_CR18","doi-asserted-by":"publisher","first-page":"5406","DOI":"10.1158\/1078-0432.CCR-17-0812","volume":"23","author":"D Meulendijks","year":"2017","unstructured":"Meulendijks D, Jacob W, Voest EE, Mau-Sorensen M, Martinez-Garcia M, Taus A, Fleitas T, Cervantes A, Lolkema MP, Langenberg MHG, De Jonge MJ, Sleijfer S, Han JY, Calles A, Felip E, Kim SW, Schellens JHM, Wilson S, Thomas M, Ceppi M, Meneses-Lorente G, James I, Vega-Harring S, Dua R, Nguyen M, Steiner L, Adessi C, Michielin F, Bossenmaier B, Weisser M, Lassen UN (2017) Phase Ib study of lumretuzumab plus cetuximab or erlotinib in solid tumor patients and evaluation of HER3 and heregulin as potential biomarkers of clinical activity. Clin Cancer Res 23:5406\u20135415","journal-title":"Clin Cancer Res"},{"key":"832_CR19","first-page":"22","volume":"14","author":"F Wang","year":"2012","unstructured":"Wang F, Flanagan J, Su N, Wang LC, Bui S, Nielson A, Wu X, Vo HT, Ma XJ, Luo Y (2012) RNAscope. a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues J Mol Diagn 14:22\u201329","journal-title":"a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues J Mol Diagn"},{"key":"832_CR20","doi-asserted-by":"publisher","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"RL Wahl","year":"2009","unstructured":"Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50:122S\u2013150S","journal-title":"J Nucl Med"},{"key":"832_CR21","doi-asserted-by":"publisher","first-page":"458","DOI":"10.4161\/mabs.20230","volume":"4","author":"NW Van de Donk","year":"2012","unstructured":"Van de Donk NW, Dhimolea E (2012) Brentuximab vedotin. MAbs 4:458\u2013465","journal-title":"MAbs"},{"key":"832_CR22","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/S1470-2045(15)70128-2","volume":"16","author":"MC Palanca-Wessels","year":"2015","unstructured":"Palanca-Wessels MC, Czuczman M, Salles G, Assouline S, Sehn LH, Flinn I, Patel MR, Sangha R, Hagenbeek A, Advani R, Tilly H, Casasnovas O, Press OW, Yalamanchili S, Kahn R, Dere RC, Lu D, Jones S, Jones C, Chu YW, Morschhauser F (2015) Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol 16:704\u2013715","journal-title":"Lancet Oncol"},{"key":"832_CR23","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1093\/annonc\/mdw401","volume":"27","author":"JF Liu","year":"2016","unstructured":"Liu JF, Moore KN, Birrer MJ, Berlin S, Matulonis UA, Infante JR, Wolpin B, Poon KA, Firestein R, Xu J, Kahn R, Wang Y, Wood K, Darbonne WC, Lackner MR, Kelley SK, Lu X, Choi YJ, Maslyar D, Humke EW, Burris HA (2016) Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. Ann Oncol 27:2124\u20132130","journal-title":"Ann Oncol"},{"key":"832_CR24","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1158\/1078-0432.CCR-16-0772","volume":"23","author":"RH Advani","year":"2017","unstructured":"Advani RH, Lebovic D, Chen A, Brunvand M, Goy A, Chang JE, Hochberg E, Yalamanchili S, Kahn R, Lu D, Agarwal P, Dere RC, Hsieh HJ, Jones S, Chu YW, Cheson BD (2017) Phase I study of the anti-CD22 antibody-drug conjugate pinatuzumab vedotin with\/without rituximab in patients with relapsed\/refractory b-cell non-hodgkin lymphoma. Clin Cancer Res 23:1167\u20131176","journal-title":"Clin Cancer Res"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00832-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-019-00832-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00832-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:37:56Z","timestamp":1678509476000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-019-00832-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,5]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["832"],"URL":"https:\/\/doi.org\/10.1007\/s10637-019-00832-1","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,5]]},"assertion":[{"value":"24 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"SS: Consultant\/advisory board member for Roche-Genentech, Novartis, Astra-Zeneca, Bristol Meyers Squibb, Merck Sharp and Dolme and Amgen. Research grant funding from Amgen, Bristol Meyers Squibb, Merck Sharp and Dolme, Merck and Genentech.CM: None.PL: None.MP: Speakers bureau\/advisory boards for Pfizer, Exelixis, Pharmacyclics, Celgene, and Bayer.OK: Employee of Genentech, Inc., shareholder of F. Hoffmann La Roche, Ltd.CL: Employee of Genentech, Inc., shareholder of F. Hoffmann La Roche, Ltd.WF: Employee of Genentech, Inc., shareholder of F. Hoffmann La Roche, Ltd.RY: Employee of Genentech, Inc., shareholder of F. Hoffmann La Roche, Ltd.FB: Employee of Genentech, Inc., shareholder of F. Hoffmann La Roche, Ltd.RJH: Advisory board member and stockholder of Telix Pharmaceuticals. Consultant for Endocyte. Research grant funding from Ipsen and ITG.DN: Employee of Genentech, Inc., shareholder of F. Hoffmann La Roche, Ltd.VL: Employee of Genentech, Inc., shareholder of F. Hoffmann La Roche, Ltd.RM: Employee of Genentech, Inc., shareholder of F. Hoffmann La Roche, Ltd.OH: Consulting for Roche, Amgen, Novartis, BMS, Merck. Speaker for Genentech, BMS, Novartis, Amgen, Sanofi, Array. Contracted research for institution from Roche-Genentech, Amgen, Arcus, Astellas, AstraZeneca, BMS, Celldex, Cytomx, GSK, Immunocore, Incyte, Iovance, Merck, Merck Serono, MedImmune, NextCure, Novartis, Parker, Pfizer, Polynoma, Regeneron.JI: Consulting for Armo Biosciences, Bio Med Valley Discoveries. Employee of Janssen Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted at 6 institutions in the United States and Australia in accordance with the International Conference on Harmonization E6 Guidelines and the principles of Good Clinical Practice. The study was approved by regulatory and ethics committees at each institution and was registered at Clinicaltrials.gov, NCT01522664. The study was sponsored by Genentech, Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}